Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders

情绪障碍新型治疗药物的神经生物学和靶标验证

• 批准号: 10703939
• 负责人: Carlos Zarate
• 金额: $ 382.11万
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10703939
• 关键词: AMPA Receptors; Adverse event; Aftercare; Age; Antidepressive Agents; Behavioral; Binding; Biological; Biological Markers; Bipolar Disorder; Brain imaging; Clinical Trials; Data; Data Analytics; Diagnosis; Dimensions; Dizziness; Dose; Double-Blind Method; Drug Kinetics; Electroencephalogram; Electrophysiology (science); Evaluation; Exhibits; Feeling suicidal; Female; Frequencies; Genes; Genetic; Glutamates; Goals; Hour; Human; Incidence; Individual; Intervention; Intravenous; Investigation; Ketamine; Link; Major Depressive Disorder; Measures; Mediating; Mediation; Mental Depression; Metabolism; Mood Disorders; Motor Activity; Mus; Naltrexone; National Institute of Mental Health; Nature; Nausea and Vomiting; Neurobiology; Neuropsychological Tests; Opioid Antagonist; Opioid Receptor; Oral; Orchiectomy; Outcome Measure; Ovariectomy; Participant; Patient Self-Report; Patients; Pattern; Penetration; Pharmaceutical Preparations; Pharmacology; Phase; Phenotype; Physiological; Placebo Control; Placebos; Plasma; Polysomnography; Pre-Clinical Model; Principal Component Analysis; Procedures; Prodrugs; Property; Proteins; Protocols documentation; Randomized; Receptor Activation; Reporting; Research; Research Domain Criteria; Resistance; Rodent; Role; Safety; Self Administration; Sex Differences; Sleep; Sleep disturbances; Suicide; Sum; Symptoms; Syndrome; System; Testosterone; Therapeutic; Therapeutic Agents; Time; Validation; Wakefulness; abuse liability; antagonist; antidepressant effect; clinical development; collected works; conditioned place preference; depressive symptoms; design; enantiomer; endogenous opioids; experience; experimental study; first-in-human; forced swim test; improved; interest; kappa opioid receptors; male; metabotropic glutamate receptor 2; mu opioid receptors; new therapeutic target; norketamine; novel; novel therapeutics; off-label use; peripheral blood; phenomenological models; preservation; receptor; recruit; screening; sex; side effect; sleep onset; suicidal; suicidal behavior; suicidal risk; symptomatology; therapy development; treatment effect; treatment response; treatment-resistant depression

This Report involves work collected under protocols 01-M-0254 (NCT00024635); 08-M-0196 (NCT00759395); 08-M-0150 (NCT00697268); 14-M-0085 (NCT02122562); 07-M-0021 (NCT00397111); 14-M-0041 (NCT02049385); 07-M-0152 (NCT00472576), 09-M-N230; 15-M-0151 (NCT 02484456), 15-M-0188 (NCT02543983), 19-M-0107 (NCT03973268), and 000101-M (NCT04821271). Results this past year: 1. Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents. TP0473292 (the active ingredient of TS-161) is a prodrug of a novel metabotropic glutamate (mGlu) 2/3 receptor antagonist being developed for the treatment of patients with depression. This was a first-in-human, phase 1, randomized, double-blind, placebo-controlled, single-ascending dose (15-400 mg TS-161) and 10-day multiple-ascending dose (50-150 mg TS-161) study in healthy subjects. Following single and multiple doses, TP0473292 was extensively converted into its active metabolite TP0178894. Plasma concentrations of TP0178894 reached peak (Cmax) within 5 hours post dose and declined with a t1/2 <13 hours. Plasma exposures of TP0178894 increased with increasing dose. TP0178894 penetrated into CSF and reached a Cmax of 9.892 ng/mL at a single dose of 100 mg, which was comparable with IC50 values of antagonist activity at mGlu2/3 receptors. The most frequently observed adverse events that showed exposure-related incidence during the study were nausea, vomiting, and dizziness. The mGlu2/3 receptor antagonist prodrug TP0473292 is safe and well-tolerated, is orally bioavailable in humans with extensive conversion into the active metabolite TP0178894 with sufficient CSF penetration to exert the anticipated pharmacological effects and is a promising candidate for further clinical development in treatment of patients with depression. 2. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. The off-label use of racemic ketamine and the FDA approval of (S)-ketamine are promising developments for the treatment of depression. Nevertheless, racemic ketamine and (S)-ketamine are controlled substances with known abuse potential and their use is associated with undesirable side effects. For these reasons, research efforts have focused on identifying alternatives. One candidate is (2R,6R)-hydroxynorketamine ((2R,6R)-HNK), a ketamine metabolite that in preclinical models lacks the dissociative and abuse properties of ketamine while retaining its antidepressant-like behavioral efficacy. (2R,6R)-HNK's mechanism of action however is unclear. We found that unlike (S)- or (R)-ketamine, (2R,6R)-HNK did not directly bind to any known or proposed ketamine targets. Extensive screening and target deconvolution experiments at thousands of human proteins did not identify any other direct (2R,6R)-HNK-protein interactions. (2R,6R)-HNK was inactive in conditioned place preference, open-field locomotor activity, and intravenous self-administration procedures. In sum, our results indicate that (2R,6R)-HNK does not share pharmacological or behavioral profile similarities with ketamine or its enantiomers. Given its pharmacological profile, we predict that (2R,6R)-HNK will exhibit a favorable safety profile in clinical trials. 3. The Dynamic Relationship Between Alpha and Beta Power and Next-Day Suicidal Ideation in Individuals With Treatment-Resistant Depression. Nocturnal wakefulness has emerged as a potential predictor of short-term suicide risk. This analysis used dynamic temporal patterns in alpha and beta power and global sleep metrics to explore the possible link between next-day suicidal ideation (NDSI) and wakefulness measures in unmedicated participants with treatment-resistant depression. Thirty-three medication-free participants with treatment-resistant depression completed overnight polysomnography. A functional data analytic approach (multilevel functional principal component analysis MFPCA) was used to preserve the oscillatory nature of the data; MFPCA PC scores were then associated with NDSI. NDSI had the strongest relationship with the second beta PC score (slope = 0.09 90% credible interval, 0.03 to 0.14), which represented an oscillating pattern that reflected disturbed sleep. Results were equivocal for wakefulness after sleep onset with NDSI and did not support a relationship between NDSI and either sleep efficiency or total sleep time, highlighting the value of information contained in oscillating electroencephalogram patterns for identifying physiological links between nocturnal wakefulness and NDSI. This study leveraged the dynamic nature of wakefulness-related electroencephalogram frequencies and provides a potential electrophysiological link between suicidal ideation and wakefulness during sleep in individuals with treatment-resistant depression. 4. Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors. Emerging evidence has implicated the endogenous opioid system in mediating ketamine's antidepressant activity in subjects with major depressive disorder. To date, mu opioid receptors have been suggested as the primary opioid receptor of interest. However, this hypothesis relies primarily on observations that the opioid antagonist naltrexone blocked the effects of ketamine in humans and rodents. This report confirms previous findings that pretreatment with naltrexone (1 mg/kg) just prior to ketamine (10 mg/kg) administration effectively blocks the behavioral effect of ketamine in the mouse forced swim test 24 h post-treatment. Furthermore, pharmacological blockade of kappa opioid receptors prior to ketamine administration with the selective, short-acting antagonist LY2444296 successfully blocked ketamine's effects in the forced swim test. Likewise, the ability of the ketamine metabolite (2R,6R)-hydroxynorketamine to reduce immobility scores in the forced swim test was also blocked following pretreatment with either naltrexone or LY2444296. These data support a potential role of kappa opioid receptors in mediating the behavioral activity of ketamine and its non-dissociate metabolite (2R,6R)-hydroxynorketamine. 5. Sex-dependent metabolism of ketamine and ( 2R,6R)-hydroxynorketamine in mice and humans. Ketamine is rapidly metabolized to norketamine and hydroxynorketamine (HNK) metabolites. In female mice, when compared to males, higher levels of (2R,6R;2S,6S)-HNK have been observed following ketamine treatment, and higher levels of (2R,6R)-HNK following the direct administration of (2R,6R)-HNK. In humans, plasma levels of ketamine and norketamine were higher in males than females, while (2R,6R;2S,6S)-HNK levels were not different. Following ketamine administration to mice (10 mg/kg i.p.), Cmax and total plasma concentrations of ketamine and norketamine were higher, and those of (2R,6R;2S,6S)-HNK were lower, in intact males compared to females. Direct (2R,6R)-HNK administration (10 mg/kg i.p.) resulted in higher levels of (2R,6R)-HNK in female mice. Ovariectomy did not alter ketamine metabolism in female mice, whereas orchidectomy recapitulated female pharmacokinetic differences in male mice, which was reversed with testosterone replacement. Sex is an important biological variable that influences the metabolism of ketamine and the HNKs, which may contribute to sex differences in therapeutic antidepressant efficacy or side effects.

本报告涉及根据协议01-M-0254 （NCT00024635）收集的工作；08 - m - 0196 (NCT00759395);08 - m - 0150 (NCT00697268);14 - m - 0085 (NCT02122562);07 - m - 0021 (NCT00397111);14 - m - 0041 (NCT02049385);07-m-0152 (nct00472576), 09-m-n230；15-M-0151 (nct02484456), 15-M-0188 (NCT02543983), 19-M-0107 （NCT03973268）和000101-M （NCT04821271）。